Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162048 | 0.74 | NPC1 (0.53) | HDAC6NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL669951 | 0.73 | GAA (0.53) | HDAC6SMN1; SMN2MEN1KMT2AHDAC2 | |
| SCHEMBL31123994 | 0.73 | RAB9A (0.40) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL31123960 | 0.73 | HDAC6 (0.47) | HDAC6NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL31162002 | 0.73 | KMT2A (0.50) | HDAC6NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL12473276 | 0.72 | HDAC6 (0.48) | HDAC6NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL31161905 | 0.72 | HDAC6 (0.46) | HDAC6NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL31162191 | 0.72 | KMT2A (0.53) | HDAC6NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11356966 | 0.71 | HDAC6 (0.47) | HDAC6NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12473329 | 0.70 | MGAM (0.57) | HDAC6NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688161-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024206357-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | HDAC6 318/4885NPC1 706/4885RAB9A 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.